Abstract:Protein kinases constitute the largest group within the kinase family, and mutations and translocations of protein kinases due to genetic alterations are intimately linked to the pathogenesis of numerous diseases. Bruton's tyrosine kinase (BTK) is a member of the protein kinases and plays a pivotal role in the development and function of B cells. BTK belongs to the tyrosine TEC family. The aberrant activation of BTK is closely associated with the pathogenesis of B-cell lymphoma. Consequently, BTK has always been a critical target for treating hematological malignancies. To date, two generations of small-molecule covalent irreversible BTK inhibitors have been employed to treat malignant B-cell tumors, and have exhibited clinical efficacy in hitherto refractory diseases. However, these drugs are covalent BTK inhibitors, which inevitably lead to drug resistance after prolonged use, resulting in poor tolerance in patients. The third-generation non-covalent BTK inhibitor Pirtobrutinib has obtained approval for marketing in the United States, thereby circumventing drug resistance caused by C481 mutation. Currently, enhancing safety and tolerance constitutes the primary issue in developing novel BTK inhibitors. This article systematically summarizes recently discovered covalent and non-covalent BTK inhibitors and classifies them according to their structures. This article also provides a detailed discussion of binding modes, structural features, pharmacological activities, advantages and limitations of typical compounds within each structure type, providing valuable references and insights for developing safer, more effective and more targeted BTK inhibitors in future studies.

Novel 6-Amino-1,3,5-triazine Derivatives As Potent BTK Inhibitors: Structure-Activity Relationship (SAR) Analysis and Preliminary Mechanism Investigation.

Structure-activity Relationship Investigation for Benzonaphthyridinone Derivatives As Novel Potent Bruton's Tyrosine Kinase (BTK) Irreversible Inhibitors.

Discovery and Structure-Activity Relationship of Novel Diphenylthiazole Derivatives As BTK Inhibitor with Potent Activity Against B Cell Lymphoma Cell Lines.

Discovery of Pyrido[3,4-B]indol-1-one Derivatives As Novel Non-Covalent Bruton's Tyrosine Kinase (BTK) Inhibitors.

Structure-activity relationship investigation for imidazopyrazole-3-carboxamide derivatives as novel selective inhibitors of Bruton's tyrosine kinase

Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-(tert-butyl)benzamide (CHMFL-BTK-01) As a Highly Selective Irreversible Bruton's Tyrosine Kinase (BTK) Inhibitor

Discovery of Pyrrolo[1,2-A]quinoxalin-4(5h)-one Derivatives As Novel Non-Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitors

Design, synthesis, and biological evaluation of pyrrolopyrimidine derivatives as novel Bruton's tyrosine kinase (BTK) inhibitors

Design, Synthesis and Biological Evaluation of Novel 3-Substituted Pyrazolopyrimidine Derivatives As Potent Bruton’s Tyrosine Kinase (BTK) Inhibitors

Discovery of Pteridine-7(8H)-one Derivatives As Potent and Selective Inhibitors of Bruton's Tyrosine Kinase (BTK).

Discovery and Biological Evaluation of N5-substituted 6,7-Dioxo-6,7-dihydropteridine Derivatives As Potent Bruton's Tyrosine Kinase Inhibitors.

Design, Synthesis and Biological Evaluation of Novel Dithiocarbamate-Substituted Diphenylaminopyrimidine Derivatives As BTK Inhibitors

Discovery and Biological Evaluation of Pyrimido[4,5-D]pyrimidine-2,4(1h,3h)-dione Derivatives As Potent Bruton’s Tyrosine Kinase Inhibitors

Discovery of new non-covalent reversible BTK inhibitors: Synthesis, in silico studies, and in vitro evaluations

Discovery of 1-Amino-1 H -imidazole-5-carboxamide Derivatives as Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitors

Recent Research of BTK Inhibitors: Methods of Structural Design, Pharmacological Activities, Manmade Derivatives and Structure-Activity Relationship.

Discovery of novel BTK PROTACs with improved metabolic stability via linker rigidification strategy

Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4-b]pyrrolizines As Novel Bruton’s Tyrosine Kinase Inhibitors

Emerging small-molecule inhibitors of the Bruton’s tyrosine kinase (BTK): Current development

Synthesis and biological evaluation of novel 1-substituted 3-(3-phenoxyprop-1-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors.